TECH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Bio-Techne Corp (TECH) is not an optimal buy for a beginner, long-term investor at this moment. The stock is currently in a pre-market decline (-0.55%), with no significant positive trading signals or strong catalysts to justify immediate investment. While analysts have raised price targets and maintain a generally positive outlook, the financial performance shows mixed results, and hedge funds are heavily selling. The technical indicators are neutral to slightly bearish, and options data suggests a bearish sentiment in open interest. For a long-term investor, it may be better to wait for a more favorable entry point or stronger positive signals.
The MACD histogram is negative (-0.573), indicating bearish momentum, though it is contracting. RSI is neutral at 41.124, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level (58.592), with support at 55.057 and resistance at 62.128. Overall, the technical indicators are neutral to slightly bearish.
Analysts have raised price targets, with several firms maintaining Buy ratings. The company's FY27 organic growth outlook appears promising, and Q4 guidance implies modest market improvements.
Hedge funds are aggressively selling, with a 5004.01% increase in selling activity last quarter. The company's revenue declined slightly (-0.39% YoY), and gross margin dropped (-1.43% YoY). Technical indicators and options data suggest bearish sentiment.
In Q2 2026, revenue dropped slightly (-0.39% YoY) to $295.88M. However, net income increased by 8.93% YoY to $38M, and EPS rose 9.09% YoY to 0.24. Gross margin declined to 65.29% (-1.43% YoY), indicating some pressure on profitability.
Analysts have raised price targets, with UBS, TD Cowen, and Citi maintaining Buy ratings and targets ranging from $79 to $80. However, some firms, like Stifel and Evercore ISI, have expressed concerns about flat mid-year growth and modest near-term market improvements.
